nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2016-3-3-37-46nodgo-245Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ/ОБЗОРЫ ЛИТЕРАТУРЫORIGINAL INVESTIGATIONS/LITERATURE REVIEWSПерспективы мультицентрового взаимодействия в Азии в области детской гематологии и онкологииPerspectives of multicenter collaboration in Asia on pediatric hematology and oncologyЛиЧ.К.LiC.K.

Гонконг;

кафедра педиатрии, Китай

MBBS, MD, FRCPCH, Continental President of Asia, Director, Hong Kong;

Professor, Department of Paediatrics

ckli@cuhk.edu.hkДетский онкологический центр им. Леди Пао при Госпитале Принца Уэльского; Китайский университет ГонконгаРоссияInternational Society of Paediatric Oncology (SIOP), Lady Pao Children’s Cancer Centre, Prince of Wales Hospital; The Chinese University of Hong Kong, ShatinRussian Federation201622092016333746Copyright © Ли Ч., 20162016Ли Ч.Li C.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/245

Азия является самым большим континентом в мире, в котором проживает около 60 % населения земли. Новых случаев детского рака в Азии выявляется более 120 000 в год. В связи с различиями в экономических системах и организации здравоохранения исходы лечения детского рака в регионах данного континента сильно разнятся. Мультицентровое взаимодействие способствует улучшению подходов к лечению детского рака, оно продемонстрировало свою эффективность во многих западных и некоторых азиатских (например, Япония) странах. Развитие мультицентрового взаимодействия должно основываться на ситуации в конкретном регионе и быть осуществимым и устойчивым. Сегодня в азиатских странах все больше и больше точек соприкосновения. Предполагается, что в Азии будут работать различные модели взаимодействия в зависимости от конкретной ситуации в стране. Передача опыта очень важна, и Конгресс SIOP Asia – 2016, прошедший недавно в Москве, стал для этого великолепной площадкой.

Авторы перевода: К.И. Киргизов, Т.В. Шаманская

Asia is the largest continent in the world which covers about 60% of world population with estimated number of new cases of childhood cancer about 120 000 per year. Due to variation in economy and health care systems, the treatment outcome of childhood cancer in Asian countries varies greatly. Multicenter collaboration is the direction for improvement of treatment outcome in childhood cancer and this has been demonstrated in many western countries and some Asian countries such as Japan. The development of multicenter collaboration must base on the local situation and be feasible and sustainable. There are now more and more collaboration happening in different countries in Asia. It is anticipated to have different models of collaboration according to the local situation and the sharing of experience is of great importance, and the recent Asia SIOP Congress at Moscow was an excellent platform for sharing.

детский ракмультицентровое взаимодействиеазиатские страныchildhood cancermulticenter collaborationAsia countriesReferencesYoshida H., Imamura T., Saito A.M. et al., for the Japan Association of Childhood Leukemia Study. Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia. PLoS One 2015;10(8):e0136428.Yoshida H., Imamura T., Saito A.M. et al., for the Japan Association of Childhood Leukemia Study. Protracted Administration of L-Asparaginase in Maintenance Phase Is the Risk Factor for Hyperglycemia in Older Patients with Pediatric Acute Lymphoblastic Leukemia. PLoS One 2015;10(8):e0136428.Manabe A., Kawasaki H., Shimada H. et al. Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04. Cancer Med 2015;4:682–9.Manabe A., Kawasaki H., Shimada H. et al. Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04. Cancer Med 2015;4:682–9.Hyakuna N., Shimomura Y., Watanabe A. et al. Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. J Pediatr Hematol Oncol 2014;36:22–9.Hyakuna N., Shimomura Y., Watanabe A. et al. Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. J Pediatr Hematol Oncol 2014;36:22–9.Guo Y., Liu T.F., Ruan M. et al. Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children. Zhongguo Dang Dai Er Ke Za Zhi (The Chinese Jounral of Contemporary Pediarics) 2015;17:819–24.Guo Y., Liu T.F., Ruan M. et al. Efficacy and safety of imatinib for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in children. Zhongguo Dang Dai Er Ke Za Zhi (The Chinese Jounral of Contemporary Pediarics) 2015;17:819–24.Liu X., Zou Y., Wang H. et al. Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol. Zhonghua Er Ke Za Zhi (The Chinese Journal of Pediatrics) 2014;52(6):449–54.Liu X., Zou Y., Wang H. et al. Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol. Zhonghua Er Ke Za Zhi (The Chinese Journal of Pediatrics) 2014;52(6):449–54.Karachunskiy A., Herold R., von Stackelberg A. et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia 2008;22(6):1144–53.Karachunskiy A., Herold R., von Stackelberg A. et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia 2008;22(6):1144–53.Karachunskiy A., Roumiantseva J., Lagoiko S. et al. Efficacy and toxicity of dexamethasone vs methylprednisolone-longterm results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002. Leukemia 2015;29(9):1955–8.Karachunskiy A., Roumiantseva J., Lagoiko S. et al. Efficacy and toxicity of dexamethasone vs methylprednisolone-longterm results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002. Leukemia 2015;29(9):1955–8.Rumiantseva Iu.V., Karachunskiĭ A.I., Aleĭnikova O.V. et al. Efficiency of the ALLMB-2002 protocol in children with acute lymphoblastic leukemia. Ter Arkh 2010;82(7):11–9.Rumiantseva Iu.V., Karachunskiĭ A.I., Aleĭnikova O.V. et al. Efficiency of the ALLMB-2002 protocol in children with acute lymphoblastic leukemia. Ter Arkh 2010;82(7):11–9.Liang D.C., Yang C.P., Liu H.C. et al. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 2015 Oct 27. Doi:10.038/tpj.2015.75.Liang D.C., Yang C.P., Liu H.C. et al. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 2015 Oct 27. Doi:10.038/tpj.2015.75.Yen H.J., Chang W.H., Liu H.C. et al. Outcomes Following Discontinuation of E. coli L-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer 2016;63:665–70.Yen H.J., Chang W.H., Liu H.C. et al. Outcomes Following Discontinuation of E. coli L-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer 2016;63:665–70.Seksarn P., Wiangnon S., Veerakul G. et al. Outcome of Childhood Acute Lymphoblastic Leukemia Treated Using the Thai National Protocols. Asian Pac J Cancer Prev 2015;16(11):4609–14.Seksarn P., Wiangnon S., Veerakul G. et al. Outcome of Childhood Acute Lymphoblastic Leukemia Treated Using the Thai National Protocols. Asian Pac J Cancer Prev 2015;16(11):4609–14.Fadoo Z., Nisat I., Yousuf F. e al. Clinical features and induction outcome of childhood acute lymphoblastic leukemia in a lower/ middle income population: A multiinstitutional report from Pakistan. Pediatr Blood Cancer 2015;62:1700–8.Fadoo Z., Nisat I., Yousuf F. e al. Clinical features and induction outcome of childhood acute lymphoblastic leukemia in a lower/ middle income population: A multiinstitutional report from Pakistan. Pediatr Blood Cancer 2015;62:1700–8.Al-Sudairy R., Al-Nasser A., Alsutan A. et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia in Saudi Arabia: a multiinstitutional retrospective national collaborative study. Pediatr Blood Cancer 2014;61:74–80.Al-Sudairy R., Al-Nasser A., Alsutan A. et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia in Saudi Arabia: a multiinstitutional retrospective national collaborative study. Pediatr Blood Cancer 2014;61:74–80.Al-Mulla N.A., Chandra P., Khattab M. et al. Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: a prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA). Pediatr Blood Cancer 2014;61(8):1403–10.Al-Mulla N.A., Chandra P., Khattab M. et al. Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: a prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA). Pediatr Blood Cancer 2014;61(8):1403–10.Yeoh A.E., Ariffin H., Chai E.L. et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol 2012;30(19):2384–92.Yeoh A.E., Ariffin H., Chai E.L. et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol 2012;30(19):2384–92.Stary J., Zimmermann M., Campbell M. et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized international trial ALL ICBFM 2002. J Clin Oncol 2014;32:174–84.Stary J., Zimmermann M., Campbell M. et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized international trial ALL ICBFM 2002. J Clin Oncol 2014;32:174–84.

The authors declare that there are no conflicts of interest present.